Global $1.75 Bn Neoantigen Cancer Vaccine Markets, 2020-2022 & 2023-2026
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "Global Neoantigen Cancer Vaccine Market, By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
The Global Neoantigen Cancer Vaccine Market is projected to grow with a CAGR of 54.18% during the forecast period and is expected to reach USD 1754.44 million by 2026.
The key factors responsible for the growth of neoantigen cancer vaccine market include rapid innovations in technology as well as infrastructural developments in healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to boost the growth of neoantigen cancer vaccine market across the globe in the coming years.
The Global Neoantigen Cancer Vaccine Market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region, and company. Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others. Out of which, the intravenous segment is expected to dominate the market through 2026 and intramuscular is anticipated to be the fastest growing segment in the forecast period.
This growth can be accredited to quick response as well as to the fact that drug dosage can be controlled easily. Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of administration segment in the coming years.
The application segment is further segregated into lung, melanoma, gastrointestinal, brain cancer, and others. The lung cancer segment is going to dominate the market in the forecast period as the neoantigen based immunotherapy of OSE Immunotherapeutic, which is in development for the Tedopi (OSE2101) neoantigen cancer vaccine is expected to launch in 2022. Tedopi (OSE2101), is used in the treatment of HLA-A2+ Lung cancer (NSCLC) patients. Currently, the vaccine is in phase III stage of clinical development.
Regionally, Asia Pacific neoantigen cancer vaccine market is expected to be the leading region over the forecast period due to the rising prevalence and incidence of cancer cases including lung cancer, melanoma, gastrointestinal, pancreatic cancer and other solid tumor indications.
Major companies operating in the market across the globe are focusing more towards expanding their share in the market.
Major players operating in the Global Neoantigen Cancer Vaccine Market include
OSE Immunotherapeutics SA
Gritstone bio, Inc
BioNTech SE
F Hoffmann-La Roche Ltd
Pfizer Inc
Merck & Co Inc
Moderna Inc
Avidea Technologies, Inc
Eli Lilly and Company
Vaccibody AS
Agenus Inc
Novogene Co, Ltd
ZIOPHARM Oncology Inc
ISA Pharmaceuticals BV
BrightPath Biotherapeutics Co, Ltd
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis, Inc
Nouscom AG
Report Scope:
Years considered for this report:
Base Year: 2020
Estimated Year: 2022
Forecast Period: 2023-2026
Global Neoantigen Cancer Vaccine Market, By Product:
Personalized neo-antigen vaccine
Off-the shelf neoantigen vaccine
Global Neoantigen Cancer Vaccine Market, By Neoantigen Type:
Synthetic Long Peptide
Nucleic acid
Dendritic cell
Tumor cell
Global Neoantigen Cancer Vaccine Market, By Route of Administration:
Intravenous
Intramuscular
Transdermal
Others
Global Neoantigen Cancer Vaccine Market, By Cell:
Autologous
Allogenic
Global Neoantigen Cancer Vaccine Market, By Technology:
RNA Sequencing
Whole Genome Sequencing
HLA Typing
Global Neoantigen Cancer Vaccine Market, By Delivery Mechanism:
Liposomes
Virosomes
Gene gun
Electroporation
Others
Global Neoantigen Cancer Vaccine Market, By Application:
Lung
Melanoma
Gastrointestinal
Brain cancer
Others
Global Neoantigen Cancer Vaccine Market, By Region:
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
Singapore
South America
Brazil
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
For more information about this report visit https://www.researchandmarkets.com/r/n4k5x7
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900